Matching slides 303,780
Current window 215,461-215,490
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

215,461-215,490 of 303,780

filter-aware
37
The slide uses a biological process diagram to illustrate drug targets (a4b7, TL1A, IL-23) and their corresponding therapeutic antibodies.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
38
The slide uses a bar chart to illustrate additive clinical remission rates, with a table below providing additional clinical metrics (N, maintenance remission, safety).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
39
The slide uses donut charts to represent remission rates and highlights the safety advantages of Spyre's gut-selective approach.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
40
Includes a specific note that this is an 'Illustrative example' and 'Preliminary; pending regulatory feedback'.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
41
The slide uses a bispecific antibody illustration to represent the combination therapy approach.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
42
The slide uses a Venn diagram to illustrate target overlap and a hierarchical tree to show potential combination therapy paths.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
43
The slide uses a comparative bar chart structure to show the delta in efficacy when using a companion diagnostic (CDx).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
44
Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slidesAeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
46
The slide uses a table-based timeline format to track R&D progress and external data readouts.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
47
The table uses a custom visualization for market cap range (min, IPO, today, max) and clinical stage progression.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
48
The table maps historical industry M&A deals to Spyre's internal pipeline development milestones (2025-2027).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
49
Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slidesAeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
50
The slide uses a list-based format to highlight key organizational milestones and metrics.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
01
Slide 1
Alkermes | Investor Presentation Deck | 56 slidesAlkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
02
Includes company overview, forward-looking statement safe harbor, SEC filing information, non-GAAP definition, and trademark disclosures.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
03
Alkermes | Investor Presentation Deck | 56 slidesAlkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
04
Alkermes | Investor Presentation Deck | 56 slidesAlkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Current Reality (Pain)1 hit
05
This is a classic 'preempt_rebuttal' style slide used in proxy contests to defend the incumbent board.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Current Reality (Pain)1 hit
06
Alkermes | Investor Presentation Deck | 56 slidesAlkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Current Reality (Pain)1 hit
07
The slide uses a four-column layout to summarize key business pillars.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Current Reality (Pain)1 hit
08
The slide uses a three-column layout to present strategic priorities, with a footer highlighting stock performance relative to peers.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Future Vision (Gain)1 hit
09
Alkermes | Investor Presentation Deck | 56 slidesAlkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Future Vision (Gain)1 hit
11
The slide uses three bar charts to demonstrate superior performance of ALKS relative to benchmarks.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Future Vision (Gain)Loop · Before After1 hit
12
The slide uses bar charts to demonstrate performance relative to an 'unaffected date' related to a shareholder activist event.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Future Vision (Gain)Loop · Before After1 hit
13
The slide highlights a 50% improvement in valuation multiple despite a decline in the NBI index multiple.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & ProofLoop · Before After1 hit
14
Alkermes | Investor Presentation Deck | 56 slidesAlkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & Proof1 hit
15
The slide highlights board changes, including specific appointments with shareholder support and the addition of diverse skill sets.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & Proof1 hit
16
The slide uses a dual-axis timeline (top and bottom) to annotate events on a stock price chart.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & Proof1 hit
17
The table categorizes products into 'Proprietary' and 'Royalty' streams.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & ProofLoop · Mece Breakdown1 hit
18
The slide uses a mix of bar charts for annual revenue and a line chart for weekly prescription growth.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & ProofLoop · Mece Breakdown1 hit